74 results found.

Metastatic Breast Cancer Clinical Trial using Palbociclib; Fulvestrant; Placebo

Pfizer - Recruiting 18 years or older.
- Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Of Fulvestrant (Faslodex?) With Or Without PD-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy.
Palbociclib; Fulvestrant; Placebo

Metastatic Breast Cancer Clinical Trial using Paclitaxel; Bevacizumab; Letrozole; Anastrozole; Exemestane; Fulvestrant; Goserelin; leuprorelin acetate

Japan Breast Cancer Research Group - Recruiting 20 years to 75 years.
- Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive HER2-negative Breast Cancer -BOOSTER Trial, a Multicenter Randomized Phase II Study-.
Paclitaxel; Bevacizumab; Letrozole; Anastrozole; Exemestane; Fulvestrant; Goserelin; leuprorelin acetate

HER2 Positive Metastatic Breast Cancers Clinical Trial using ONT-380; Capecitabine; Trastuzumab

Oncothyreon Inc. - Recruiting 18 years or older.
- A Phase 1b, Open-label Study to Assess the Safety and Tolerability of ONT-380 Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer.
ONT-380; Capecitabine; Trastuzumab

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Ca Clinical Trial using fulvestrant; anastrozole

Alliance for Clinical Trials in Oncology - Recruiting 18 years or older.
- Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study.
fulvestrant; anastrozole

Breast Cancer Clinical Trial

Genentech - Recruiting 18 years or older.
- An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast Cancer (SystHERs Registry (Systematic Therapies for HER2+ Metastatic Breast Cancer Study))..

Metastatic Breast Cancer Clinical Trial using PF-05280014; Paclitaxel; Herceptin®

Pfizer - Recruiting 18 years or older.
- A Phase 3 Randomized, Double-Blind Study Of PF-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel For The First-Line Treatment Of Patients With HER2-Positive Metastatic Breast Cancer.
PF-05280014; Paclitaxel; Herceptin®

HER2 Positive Breast Cancers Clinical Trial using ONT-380; T-DM1

Oncothyreon Inc. - Recruiting 18 years or older.
- A Phase 1b, Open-label Study to Assess the Safety and Tolerability of ONT-380 Combined With T-DM1.
ONT-380; T-DM1

HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Br Clinical Trial using laboratory biomarker analysis; pharmacological study; questionnaire administration; fluorine F 18-clevudine; positron emission tomography/computed tomography

University of Southern California - Recruiting 18 years or older.
- Development of an In Vivo Cell Proliferation Marker for PET Assessment of Chemotherapeutic Response in Cancer.
laboratory biomarker analysis; pharmacological study; questionnaire administration; fluorine F 18-clevudine; positron emission tomography/computed tomography

Breast Cancer Clinical Trial using Trastuzumab

Northwestern University - Recruiting 18 years or older.
- Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer.
Trastuzumab

Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breas Clinical Trial using therapeutic conventional surgery; radiation therapy; quality-of-life assessment

Roswell Park Cancer Institute - Recruiting 50 years or older.
- Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer.
therapeutic conventional surgery; radiation therapy; quality-of-life assessment

Breast Cancer Clinical Trial using MM-302 Monotherapy; MM-302 in combination with trastuzumab; MM-302 in combination with trastuzumab q3w; MM-302 in combination with trastuzumab and cyclophosphamide

Merrimack Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer.
MM-302 Monotherapy; MM-302 in combination with trastuzumab; MM-302 in combination with trastuzumab q3w; MM-302 in combination with trastuzumab and cyclophosphamide

Metastatic Breast Cancer Clinical Trial using TDM1; Lapatinib; Abraxane

The Methodist Hospital System - Recruiting 18 years or older.
- Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients.
TDM1; Lapatinib; Abraxane

Breast Cancer Clinical Trial using trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- A Single Arm Multi-center Study Investigating the at Home Administration of Trastuzumab Subcutaneous Vial for the Treatment of Patients With HER2-positive Early Breast Cancer..
trastuzumab [Herceptin]

Breast Cancer Clinical Trial using pertuzumab; trastuzumab; Aromatase Inhibitor; Induction Chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Two-arm, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-positive and Hormone Receptor-positive Advanced (Metastatic or Locally Advanced) Breast Cancer..
pertuzumab; trastuzumab; Aromatase Inhibitor; Induction Chemotherapy

Breast Cancer Clinical Trial using taxane; pertuzumab; trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer.
taxane; pertuzumab; trastuzumab [Herceptin]

Breast Cancer Clinical Trial using trastuzumab emtansine; trastuzumab

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy.
trastuzumab emtansine; trastuzumab

Breast Cancer Clinical Trial using trastuzumab emtansine

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.
trastuzumab emtansine

Breast Cancer Clinical Trial using trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Randomized, Multicenter Phase III Study in Patients With HER2-positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab.
trastuzumab [Herceptin]

Breast Cancer Clinical Trial using trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study].
trastuzumab [Herceptin]

Breast Cancer Clinical Trial using Kadcyla (trastuzumab emtansine)

Hoffmann-La Roche - Recruiting 18 years or older.
- A Two-cohort, Open-label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-based Treatment..
Kadcyla (trastuzumab emtansine)

Breast Cancer Clinical Trial using trastuzumab emtansine [Kadcyla]; trastuzumab [Herceptin]; pertuzumab [Perjeta]; taxane; anthracycline-based chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINES AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2?POSITIVE PRIMARY BREAST CANCER.
trastuzumab emtansine [Kadcyla]; trastuzumab [Herceptin]; pertuzumab [Perjeta]; taxane; anthracycline-based chemotherapy

Advanced HER2-positive Breast Cancer or Gastric Cancer Clinical Trial using LJM716; Trastuzumab

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer.
LJM716; Trastuzumab

Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Car Clinical Trial using niraparib; Physician's choice

Tesaro, Inc. - Recruiting 18 years or older.
- A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients.
niraparib; Physician's choice

Breast Cancer Clinical Trial using Lapatinib; Herceptin

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase 2 Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer.
Lapatinib; Herceptin

Breast Cancer Clinical Trial using ABP 980; trastuzumab; epirubicin; cyclophosphamide; paclitaxel; Lumpectomy or mastectomy with sentinel node or axillary node dissection

Amgen - Recruiting 18 years or older.
- A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer.
ABP 980; trastuzumab; epirubicin; cyclophosphamide; paclitaxel; Lumpectomy or mastectomy with sentinel node or axillary node dissection

Metastatic Breast Cancer With Intracranial Metastases Clinical Trial using cabazitaxel; lapatinib

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases.
cabazitaxel; lapatinib

Breast Cancer Clinical Trial using Taxane chemotherapy; Perjeta (pertuzumab); Herceptin (trastuzumab)

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Multicentre, Phase IIIb Study With Intravenous Administration of Pertuzumab, Subcutaneous Trastuzumab, and a Taxane in Patients With HER2-positive Metastatic Breast Cancer.
Taxane chemotherapy; Perjeta (pertuzumab); Herceptin (trastuzumab)

Breast Cancer Clinical Trial using pertuzumab; placebo; trastuzumab [Herceptin]; Chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized Multicenter, Double-blind, Placebo-controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.
pertuzumab; placebo; trastuzumab [Herceptin]; Chemotherapy

Neoplasms, Breast Clinical Trial using lapatinib; trastuzumab; Aromatase inhibitor

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase III Trial to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus an Aromatase Inhibitor (AI) vs. Trastuzumab Plus an AI vs. Lapatinib Plus an AI as 1st- or 2nd- Line Therapy in Postmenopausal Subjects With Hormone Receptor+, HER2+ Metastatic Breast Cancer (MBC) Who Received Prior Trastuzumab and Endocrine Therapies.
lapatinib; trastuzumab; Aromatase inhibitor

HER2-positive, Newly Diagnosed, Primary Breast Cancer, Neoadjuvan Clinical Trial using BKM120; Trastuzumab; Paclitaxel; Placebo

Novartis - Recruiting 18 years or older.
- NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer.
BKM120; Trastuzumab; Paclitaxel; Placebo

Breast Cancer Clinical Trial using trastuzumab [Herceptin]; taxane; anthracycline

Hoffmann-La Roche - Recruiting 18 years or older.
- NATIONAL PHASE IIIB PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, OPEN LABEL STUDY TO ASSESS THE SAFETY OF SUBCUTANEOUS TRASTUZUMAB AND MOLECULAR BIOMARKERS IN PATIENTS WITH EARLY AND LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER.
trastuzumab [Herceptin]; taxane; anthracycline

Breast Cancer Clinical Trial using trastuzumab [Herceptin]; paclitaxel; docetaxel; carboplatin; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE IIIB STUDY WITH SUBCUTANEOUS ADMINISTRATION OF TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER TO EVALUATE PATIENT SATISFACTION.
trastuzumab [Herceptin]; paclitaxel; docetaxel; carboplatin; chemotherapy

Breast Cancer, HER-2 Positive Breast Cancer, or Triple Negative B Clinical Trial using ganetespib

Synta Pharmaceuticals Corp. - Recruiting 18 years or older.
- An Open Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib(STA-9090) Monotherapy in Women With Previously Untreated Metastatic HER2 Positive or Triple Negative Breast Cancer.
ganetespib

HER2-positive Metastatic Breast Cancer Clinical Trial using Trastuzumab; Pertuzumab; Paclitaxel; Vinorelbine; T-DM1

Swiss Group for Clinical Cancer Research - Recruiting 18 years or older.
- A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer.
Trastuzumab; Pertuzumab; Paclitaxel; Vinorelbine; T-DM1

Breast Neoplasm Clinical Trial

Medica Scientia Innovation Research - Recruiting 18 years or older.
- Observational, Retrospective and Multicenter Study to Evaluate the Clinical Benefit of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib.

Breast Cancer Clinical Trial using trastuzumab [Herceptin]; paclitaxel; docetaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Single Arm, Open-Label PhIV Study to Investigate the Effect of First-Line Herceptin (Trastuzumab) in Combination With a Taxane in Patients With Metastatic Breast Cancer Who Relapsed After Receiving (Neo)Adjuvant Herceptin for HER2-Positive Early Breast Cancer.
trastuzumab [Herceptin]; paclitaxel; docetaxel

Breast Cancer, HER2 Positive Breast Cancer, or HER2 Negative Brea Clinical Trial using Biomarker Analysis

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer.
Biomarker Analysis

HER2-positive Breast Cancer, or TNM Stage II-IV Breast Cancer Clinical Trial

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting N/A or older.
- CharactHer: A Study of the Molecular and Cytogenetic Characteristics of HER2-positive Breast Cancers to Predict Durable Complete Response After Chemotherapy and Trastuzumab.

Her2 Positive Metastatic Breast Cancer Clinical Trial using non-pegylated liposomal doxorubicon (MyocetT); Lapatinib (TyverbT)

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- A Phase I/II Study of Lapatinib Plus Myocet TM in Patients With HER2+ve Metastatic Breast Cancer Following Disease Progression During, or After, Treatment With Trastuzumab and Taxanes.
non-pegylated liposomal doxorubicon (MyocetT); Lapatinib (TyverbT)

HER2-positive Breast Cancer, Recurrent Breast Cancer, or Stage IV Clinical Trial using pertuzumab; trastuzumab; paclitaxel albumin-stabilized nanoparticle formulation; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 19 years or older.
- Phase II Prospective Open Label Single Arm Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Metastatic Breast Cancer.
pertuzumab; trastuzumab; paclitaxel albumin-stabilized nanoparticle formulation; laboratory biomarker analysis

Breast Cancer Clinical Trial using BYL719; BKM120; Placebo

Novartis - Recruiting 18 years or older.
- A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer.
BYL719; BKM120; Placebo

Breast Cancer Clinical Trial using trastuzumab [Herceptin]; Chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open Label, Randomised Phase II Study Assessing Quality of Life Associated With Subcutaneous Trastuzumab Injected Into the Thigh or Upper Arm in Patients With HER2-positive Early Breast Cancer.
trastuzumab [Herceptin]; Chemotherapy

Breast Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- CLINICAL PRACTICE SURVEILLANCE OF THE USE OF HERCEPTIN SUBCUTANEOUS IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER (HerSCin).

HER2-positive Breast Cancer, Inflammatory Breast Cancer, Male Bre Clinical Trial using entinostat; lapatinib ditosylate; trastuzumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed.
entinostat; lapatinib ditosylate; trastuzumab; laboratory biomarker analysis

Breast Cancer, or HER2 Positive Clinical Trial using PTC+Pertuzumab; FEC-T+Pertuzumab

The Netherlands Cancer Institute - Recruiting 18 years or older.
- Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 Study.
PTC+Pertuzumab; FEC-T+Pertuzumab

Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Ca Clinical Trial using docetaxel; carboplatin; trastuzumab; pertuzumab; goserelin acetate; therapeutic conventional surgery; whole breast irradiation; quality-of-life assessment; laboratory biomarker analysis; aromatase inhibition therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation.
docetaxel; carboplatin; trastuzumab; pertuzumab; goserelin acetate; therapeutic conventional surgery; whole breast irradiation; quality-of-life assessment; laboratory biomarker analysis; aromatase inhibition therapy

Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Clinical Trial using Blood test

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- Identification of Early Markers of Response and Resistance to Trastuzumab in Patients With Localized Human Epidermal Growth Factor Receptor-2(HER-2)-Positive Breast Cancer Candidates for Breast Conserving Surgery.
Blood test

Advanced, Metastatic Breast Cancer Clinical Trial using LEE011; Letrozole; Letrozole Placebo

Novartis - Recruiting N/A or older.
- A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease.
LEE011; Letrozole; Letrozole Placebo

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Ca Clinical Trial using systemic chemotherapy; tamoxifen citrate; anastrozole; exemestane; letrozole

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE III, RANDOMIZED CLINICAL TRIAL OF STANDARD ADJUVANT ENDOCRINE THERAPY +/-CHEMOTHERAPY IN PATIENTS WITH 1-3 POSITIVE NODES, HORMONE RECEPTOR-POSITIVE AND HER2-NEGATIVE BREAST CANCER WITH RECURRENCE SCORE (RS) OF 25 OR LESS. RXPONDER: A CLINICAL TRIAL RX FOR POSITIVE NODE, ENDOCRINE RESPONSIVE BREAST CANCER.
systemic chemotherapy; tamoxifen citrate; anastrozole; exemestane; letrozole

HER2-negative Und Hormone-receptor Positive Metastatic Breast Can Clinical Trial using Everolimus in combination with standard endocrine therapy

University of Ulm - Recruiting 18 years or older.
- DETECT IV - A Multicenter Single Arm Phase II Study to Investigate the Clinical Efficacy of Everolimus in Combination With Endocrine Therapy in Postmenopausal Patients With Hormone-receptor Positive, HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells..
Everolimus in combination with standard endocrine therapy

Breast Neoplasms Clinical Trial using Trastuzumab; pertuzumab; lapatinib

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib.
Trastuzumab; pertuzumab; lapatinib

HER-2 Positive Breast Cancer Clinical Trial using Everolimus; Vinorelbine; Trastuzumab

UNC Lineberger Comprehensive Cancer Center - Recruiting 21 years or older.
- A Phase II Study Evaluating The Efficacy And Tolerability Of Everolimus (RAD001) In Combination With Trastuzumab And Vinorelbine In The Treatment Of Progressive HER2-Positive Breast Cancer Brain Metastases.
Everolimus; Vinorelbine; Trastuzumab

HER2-positive Metastatic Breast Cancer Clinical Trial using Trastuzumab; Paclitaxel

Biocad - Recruiting 18 years to 70 years.
- International Multicenter Randomized Double Blind Phase III Clinical Trial Comparing Safety and Efficacy of BCD-022 (CJSC BIOCAD, Russia) Used With Paclitaxel to Herceptinr (F. Hoffmann-La Roche Ltd, Switzerland) Used With Paclitaxel in the First-line Treatment of HER2-positive Metastatic Breast Cancer Patients.
Trastuzumab; Paclitaxel

Breast Cancer Clinical Trial using Enzalutamide; exemestane; Placebo (for enzalutamide)

Medivation, Inc. - Recruiting 18 years or older.
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal.
Enzalutamide; exemestane; Placebo (for enzalutamide)

Breast Cancer, Gastric Cancer Clinical Trial using trastuzumab emtansine; capecitabine

Hoffmann-La Roche - Recruiting 18 years or older.
- PHASE I FOLLOWED BY PHASE II STUDY OF THE COMBINATION OF TRASTUZUMAB EMTANSINE (T-DM1) AND CAPECITABINE IN HER2-POSITIVE METASTATIC BREAST CANCER AND HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER PATIENTS.
trastuzumab emtansine; capecitabine

Metastatic Breast Cancer, or Carcinomatous Meningitis Clinical Trial using Trastuzumab

Institut Curie - Recruiting 18 years or older.
- Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis.
Trastuzumab

Breast Cancer, or Stage IV Breast Cancer Clinical Trial using positron emission tomography; copper Cu 64-DOTA-trastuzumab; Biopsy; Immunohistochemistry staining method; laboratory biomarker analysis; mutation analysis

City of Hope Medical Center - Recruiting 18 years or older.
- 64 Cu-DOTA-Trastuzumab Positron Emission Tomography in Women With Advanced HER2 Positive Invasive Breast Cancer.
positron emission tomography; copper Cu 64-DOTA-trastuzumab; Biopsy; Immunohistochemistry staining method; laboratory biomarker analysis; mutation analysis

Breast Cancer Clinical Trial using BKM120 Matching placebo; Fulvestrant; BKM120

Novartis - Recruiting 18 years or older.
- A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
BKM120 Matching placebo; Fulvestrant; BKM120

Breast Cancer Clinical Trial using Lapatinib; Trastuzumab; Endocrine Therapy; Paclitaxel

SOLTI Breast Cancer Research Group - Recruiting 18 years or older.
- PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer.
Lapatinib; Trastuzumab; Endocrine Therapy; Paclitaxel

Breast Neoplasms, HER2 Protein, Human, or Geriatric Health Servic Clinical Trial using Lapatinib; Trastuzumab; laboratory biomarker analysis; pharmacological study

City of Hope Medical Center - Recruiting 60 years or older.
- Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer.
Lapatinib; Trastuzumab; laboratory biomarker analysis; pharmacological study

Metastatic Beast Cancer Clinical Trial using Exemestane; Cyclophosphamide

New York University School of Medicine - Recruiting 18 years or older.
- Phase II Trial of Exemestane With Immunomodulatory Cyclophosphamide in ER and/or PR-positive and HER2/Neu Negative Metastatic Breast Cancer.
Exemestane; Cyclophosphamide

Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-posit Clinical Trial using veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors.
veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

Breast Cancer Clinical Trial using Adriamycin+Cyclophosphamide>Docetaxel; GnRHa with Tamoxifen

Asan Medical Center - Recruiting 20 years or older.
- A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer.
Adriamycin+Cyclophosphamide>Docetaxel; GnRHa with Tamoxifen

HER-2 Positive Breast Cancer Clinical Trial using T-DM1; 89Zr-trastuzumab

Jules Bordet Institute - Recruiting 18 years or older.
- Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1.
T-DM1; 89Zr-trastuzumab

Breast Cancer Clinical Trial using pertuzumab in combination with trastuzumab and paclitaxel

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer.
pertuzumab in combination with trastuzumab and paclitaxel

Metastatic Breast Cancer HR+, HER2- Clinical Trial using Fulvestrant; BKM120; BKM120 matching placebo

Novartis - Recruiting 18 years or older.
- A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor Based Treatment.
Fulvestrant; BKM120; BKM120 matching placebo

Carcinoma Breast Stage I, or HER2 Positive Breast Cancer Clinical Trial using Trastuzumab; Placebo

Tata Memorial Hospital - Recruiting 18 years or older.
- A Phase III Double Blind Randomized Placebo Controlled Study of Trastuzumab as Short Duration Preoperative Therapy in Patients With HER2-neu Positive Operable Breast Cancer.
Trastuzumab; Placebo

Breast Cancer Clinical Trial using Paclitaxel; Trastuzumab; Neratinib; Doxorubicin; Cyclophosphamide

National Surgical Adjuvant Breast and Bowel Project (NSABP) - Recruiting 18 years or older.
- A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens With Weekly Paclitaxel Plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide With Postoperative Trastuzumab in Women With Locally Advanced HER2-Positive Breast Cancer.
Paclitaxel; Trastuzumab; Neratinib; Doxorubicin; Cyclophosphamide

Metastatic Breast Cancer Clinical Trial using Lapatinib; Metformin

Fondazione Michelangelo - Recruiting 18 years or older.
- Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With HER2-negative, ER and/or PgR Positive Metastatic Brest Cancer With Progressive Disease After First-line Therapy.
Lapatinib; Metformin

HER2-negative Metastatic Breast Cancer, or HER2-positive Circulat Clinical Trial using standard chemo- or endocrine therapy; standard chemo- or endocrine therapy + Lapatinib

Heinrich-Heine University, Duesseldorf - Recruiting 18 years or older.
- DETECT III - A Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients With Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells.
standard chemo- or endocrine therapy; standard chemo- or endocrine therapy + Lapatinib

Breast Cancer Clinical Trial using trastuzumab; parenteral chemotherapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Persephone: Duration of Trastuzumab With Chemotherapy in Women With Early Stage Breast Cancer: Six Months Versus Twelve.
trastuzumab; parenteral chemotherapy

Breast Cancer, or Neoplasm Metastasis Clinical Trial using Non pegylated liposomal doxorubicin, trastuzumab, docetaxel

Catharina Ziekenhuis Eindhoven - Recruiting 18 years or older.
- Phase II Multicentre Open Label Study Evaluating the Efficacy and Safety of Liposomal Doxorubicin, Trastuzumab, Docetaxel as First-line Treatment of Patients With HER2 Positive Metastatic Breast Cancer.
Non pegylated liposomal doxorubicin, trastuzumab, docetaxel

HER-2 Positive Breast Cancer Clinical Trial using Trastuzumab

National Institute for Cancer Research, Italy - Recruiting 18 years or older.
- Neoadjuvant Therapy With FEC Followed by Weekly Paclitaxel and Concurrent Trastuzumab in Her2 Positive Non Operable Breast Cancer. Phase II Study..
Trastuzumab

Breast Cancer Clinical Trial using docetaxel; vinorelbine; trastuzumab

Danish Breast Cancer Cooperative Group - Recruiting 18 years to 74 years.
- A Randomised Phase III Study of Trastuzumab-Docetaxel vs Trastuzumab-Vinorelbine as 1. Line Therapy for Patients With Metastatic HER2 Positive Breast Cancer.
docetaxel; vinorelbine; trastuzumab